KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Raw Materials (2016 - 2018)

Historic Raw Materials for Travere Therapeutics (TVTX) over the last 4 years, with Q1 2018 value amounting to $3.7 million.

  • Travere Therapeutics' Raw Materials rose 1785.26% to $3.7 million in Q1 2018 from the same period last year, while for Mar 2018 it was $3.7 million, marking a year-over-year increase of 1785.26%. This contributed to the annual value of $3.4 million for FY2017, which is 15711.08% up from last year.
  • Travere Therapeutics' Raw Materials amounted to $3.7 million in Q1 2018, which was up 1785.26% from $3.4 million recorded in Q4 2017.
  • Travere Therapeutics' Raw Materials' 5-year high stood at $3.7 million during Q1 2018, with a 5-year trough of $232000.0 in Q2 2016.
  • Over the past 4 years, Travere Therapeutics' median Raw Materials value was $2.3 million (recorded in 2016), while the average stood at $2.0 million.
  • Its Raw Materials has fluctuated over the past 5 years, first surged by 36228.37% in 2016, then soared by 1785.26% in 2018.
  • Travere Therapeutics' Raw Materials (Quarter) stood at $289000.0 in 2015, then skyrocketed by 362.28% to $1.3 million in 2016, then soared by 157.11% to $3.4 million in 2017, then grew by 8.97% to $3.7 million in 2018.
  • Its last three reported values are $3.7 million in Q1 2018, $3.4 million for Q4 2017, and $3.2 million during Q1 2017.